priors.science/reviews/giant-cell-arteritis

Giant Cell Arteritis

The current evidence on 8 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

8claims tracked

67primary papers reviewed

9 Aug 2026latest evidence review

Weeklyre-scored against new papers

2 Established · 5 Likely · 1 Uncertain · 0 Doubtful | four-reviewer panel · PICO Framework

ClaimStandingEvidence certaintyCorpus

Glucocorticoid monotherapy relapses on taperGlucocorticoidEstablished88%10

Tocilizumab sustains glucocorticoid-free remissionTocilizumabEstablished87%10

Relapse common after tocilizumab discontinuationTocilizumabLikely83%10

Temporal artery halo sign diagnosticImagingLikely80%13

Large-vessel ultrasound adds sensitivityImagingLikely80%9

Upadacitinib induces remissionEmergingLikely72%9

Glucocorticoids reduce vision lossGlucocorticoidLikely72%10

Secukinumab maintains remissionEmergingUncertain55%7

Track Giant Cell Arteritis.

These claims are re-scored against new papers every week. Track this topic for the full review, including each claim’s challenge and the papers behind it.

Track this topic →

Standing — what the evidence certainty means

Established≥ 85%Strong, consistent evidence. Unlikely to change.

Likely70–84%Well supported, with some gaps or indirect evidence.

Uncertain50–69%Mixed or limited evidence. Genuinely open.

Doubtful30–49%Little support; the weight of evidence leans against it.

Refuted< 30%The evidence contradicts it — confidently false as stated.